Difference between revisions of "Ramucirumab (Cyramza)"
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 4/21/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm394260.htm FDA approved] "for the treatment of patients with advanced or metastatic, [[Gastric cancer | gastric or gastroesophageal junction (GEJ) adenocarcinoma]] with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy." | + | * 4/21/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm394260.htm FDA approved] "for the treatment of patients with advanced or metastatic, [[Gastric cancer | gastric or gastroesophageal junction (GEJ) adenocarcinoma]] with disease progression on or after prior treatment with fluoropyrimidine- or [http://hemonc.org/wiki/Category:Platinum_agents platinum-]containing chemotherapy." |
* 11/5/2014: Indication expanded "for use in combination with [[Paclitaxel (Taxol) | paclitaxel]] for the treatment of patients with advanced [[Gastric cancer | gastric or gastroesophageal junction (GEJ) adenocarcinoma]]." | * 11/5/2014: Indication expanded "for use in combination with [[Paclitaxel (Taxol) | paclitaxel]] for the treatment of patients with advanced [[Gastric cancer | gastric or gastroesophageal junction (GEJ) adenocarcinoma]]." | ||
Revision as of 00:32, 6 November 2014
General information
Class/mechanism: Recombinant human IgG1 monoclonal antibody, VEGFR2 (vascular endothelial growth factor receptor 2) antagonist. Ramucirumab binds VEGFR2 and blocks VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D, which inhibits angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ramucirumab (Cyramza) patient drug information (Chemocare)[4]
- Ramucirumab (Cyramza) package insert[1]
- Ramucirumab (Cyramza) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 4/21/2014: FDA approved "for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy."
- 11/5/2014: Indication expanded "for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma."
Also known as
IMC-1121B.